Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Inclusion Criteria: * Men or women aged 18 75, inclusive * Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of bowel * Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥ 2 and \> 15 cm of involvement beyond the anal verge Exclusion Criteria: * Women with a positive pregnancy test, who are breastfeeding, or who intend to become pregnant during the course of the study * Diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis * Presence of ileostomy or colostomy, or history of prior colon resection * Patients with planned hospitalization or surgery during the course of the study * Known allergy to milk proteins, red meat or cornstarch * Stools positive for enteric infection, including parasitic, or C. difficile toxin within 28 days of screening * Documented presence of Hetatitis B (HBsAg), Hepatitis C (HCV), or HIV * Presence of dysplasia of any grade on colonoscopic biopsies * Treatment for cancer (excluding non-melanomatous cancer of the skin or cervical carcinoma in situ) or lymphoproliferative disorder (including lymphoma) within 5 years * History of tuberculosis (TB) or Listeria infection, or known exposure to another person with active TB disease within 12 weeks of screening; or history of past or current infection with different opportunistic infections * History of TNF inhibitor (infliximab, adalimumab or certolizumab pegol) use with primary treatment failure. Secondary …